FDA Warns Cipla Over Cross-Contamination Concerns
The US Food and Drug Administration (FDA) on Tuesday released a warning letter to sent to a Goa, India-based manufacturing site of pharmaceutical company Cipla. Following a more than week-long inspection last September, FDA uncovered cross-contamination of products, noting, “Your testing confirmed the presence of active ingredients from a previous product in batches of the next product.” And the firm’s “lack of a clear root cause casts doubt on whether you have fully resolved a serious cross-contamination problem,” FDA said. The agency acknowledged that the site has suspended production in several sterile units. The firm also failed to adequately investigate “excessive and atypical High Efficiency Particulate Air (HEPA) filters failures in a short period. More than 45 filters failed due to side leakages and media failures,” FDA said. The failures impacted about 80 batches of pharmaceuticals intended for the US market, the letter says. In resolving the issues identified, FDA called on C...